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	The	bladder	 is	one	of	 the	most	common	sites	of	
cancer	in	the	urinary	tract.	Bladder	tumors	are	manifesta-
tions	of	a	multifocal	disease	whose	natural	history	has	not	
been	completely	elucidated	and	the	response	of	bladder	
tumors	to	radio	—	and	chemotherapy	is	unpredictable.
Urothelial	carcinogenesis	in	the	rat	goes	through	
a	sequence	of	morphologic	changes	beginning	as	
simple	hyperplasia.	It	then	progresses	to	nodular	and	
papillary	hyperplasia.	These	progress	 to	papillomas	
and	can	eventually	progress	to	higher-grade,	noninva-
sive	carcinomas	and	ultimately	to	invasive	neoplasms	
(Fig.	1)	[0,	7].	Many	exophytic	tumors	induced	in	rats	
are	polypoid,	often	pedunculated	and	with	an	inverted	
papillary	growth	pattern	[7].	Nodular	hyperplasia,	in	
mice,	 is	considerably	more	common	 than	papillary	
proliferations	and	nodular	hyperplasia	frequently	oc-
curs	with	a	complete	absence	of	papillary	hyperplasia	
[3].	Thus,	the	rat	model	strongly	resembles	papillary	
neoplasms	and	the	mouse	model	resembles	flat	uro-
thelial	lesions,	both	identified	in	man	[8].	
Since	the	Surgeon	Dr.	Rehn	first	suggested	a	role	
for	aniline	dye	in	the	etiology	of	bladder	cancer	in	1895,	
this	has	became	the	neoplasic	disease	which	has	been	
traditionally	most	strongly	linked	to	occupational	and	envi-
ronmental	exposure	to	chemicals	[83].	To	study	urothelial	
carcinogenesis	it	is	possible	to	use	dogs,	rabbits,	guinea	
pigs,	hamster,	rats	and	mice.	However,	for	investigation	
of	chemical	carcinogenesis	mice	and	rats	are	generally	
used,	for	several	reasons.	For	example,	in	addition	to	ben-
efits	related	to	size,	there	is	an	abundance	of	information	
concerning	the	biological	characteristics	of	neoplastic	de-
velopment	in	these	species.	This	is	why	we	have	focused	
this	review	on	urothelial	carcinogenesis	in	rats	and	mice.	
However,	other	animals	are	also	mentioned.
Fig. 1. Pathogenic	pathways	of	 rat	and	mice	urinary	bladder	
carcinogenesis
This	review	focuses	on	several	in vivo and	in vitro	ro-
dent	urinary	bladder	cancers	that	have	been	established	
over	the	past	40	years.	In	Fig.		we	present	the	potential	
applications	of	rodent	bladder	specimens	obtained	fol-
lowing	chemical	carcinogenesis	of	the	urothelium.
The rodenT bladder
The	structure	and	function	of	rodents’	lower	urinary	
tract	is	remarkably	similar	to	that	of	humans	[7].	It	ex-
tends	from	the	renal	pelvis	through	the	ureters,	urinary	
bladder,	and	into	the	urethra	[90].	Excluding	the	urethra,	
the	urinary	tract	consists	of	four	layers:	mucosa,	lamina	
propria,	muscular	and	serosa	[1,	4,	5].	The	mucosa	
of	 the	 lower	urinary	 tract	has	been	 referred	 to	as	a	
transitional	cell	epithelium	or	as	an	urothelium.	In	the	
urinary	bladder	it	is	made	up	of	three	cell	layers:	super-
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ficial,	intermediate	and	basal	[1,	7].	Since	the	entire	
urinary	tract	is	lined	with	urothelium,	theoretically	the	
urethra	and	ureters	could	develop	similar	proliferative	
lesions.	However,	induced	ureter	and	urethral	prolifera-
tive	lesions	are	rare	in	the	rat.	The	reason	for	this	may	
be	explained	by	the	quick	passage	of	urine	containing	
toxicants,	compared	to	the	more	lengthy	contact	taking	
place	in	the	urinary	bladder	[30].
Fig. 2. Potential	applications	of	bladder	samples
sponTaneous Tumors
The	 incidence	of	spontaneous	 tumors	 in	 rodents	
plays	an	important	practical	role	 in	the	design	and	in-
terpretation	of	carcinogenicity	bioassays.	The	effect	of	
a	weak	carcinogen	may	be	more	readily	detected	if	it	is	
not	obscured	by	a	background	incidence	of	spontaneous	
bladder	tumors,	so	the	choice	of	test	strain	is	important	
[51].	However,	most	naturally	occurring	strains	of	rodent	
do	not	develop	spontaneous	bladder	cancer,	more	than	
99%	are	predominantly	associated	with	advancing	age	
[11,	16,	18].	An	exceptionally	high	incidence	of	urothelial	
and	ureteric	neoplasms	have	been	reported	in	two	rat	
strains,	Brown/Norway	(BN/RijHsd) and Dark	Agouti	
(DA/OlaHsd),	which	were	associated	with	the	presence	
of	calculi	 [10,	79].	Lesions	 identified	 in	 those	animals	
were	classified	as	papillary	and	multifocal,	with	simulta-
neous	carcinoma	in situ	(CIS)	[4,	77].	Other	spontane-
ous	non-neoplasic	changes	such	as	inflammation	and	
epithelial	hyperplasia	occur	infrequently	in	the	bladder.	
Some	spontaneous	bladder	tumors	in	rats	can	generally	
be	explained	by	infection	by	the	bladder	parasite	Tricho-
somoides crassicauda	[19].	The	complications	induced	
by	this	parasite	in	experiments	on	rat	bladder	carcinogen-
esis	are	uncommon,	since	noninfected	rats	maintained	
under	optimal	conditions	do	not	become	infected	[14].	
There	are	no	known	reports	of	parasitic	infection	of	the	
mouse	bladder.	Spontaneous	bladder	tumors	in	other	
rodent	species	 including	hamsters,	guinea	pigs,	and	
rabbits	appear	equally	as	rarely	as	in	mice	[18].
requiremenTs For appropriaTe 
animal models oF urinary bladder 
carcinogenesis
Appropriate	and	valid	animal	models	 for	urinary	
bladder	carcinogenesis	must	be	similar	to	human	blad-
der	cancer	in	their	histology,	biochemical	properties,	
molecular	and	genetic	characteristics,	natural	history,	
and	biological	behaviour	 [96].	A	simple	and	natural	
method	for	the	administration	of	the	carcinogen	is	re-
quired;	the	carcinogen	ought	to	be	not	toxic	and	should	
affect	only	 the	urothelium.	The	 incidence	of	 tumors	
should	be	reliable	and	high	and	the	tumor	induction	
time	should	be	relatively	short	[69].	The	investigator	
should	be	able	to	monitor	the	experiment	or	be	able	
to	predict	results.	Some	of	the	requirements	to	animal	
models	are	listed	in	Table	1.	
Table 1. Requirements for appropriate animal models to study 
experimental bladder carcinogenesis
Histology The tumor should be of urothelial origin, with different 
stages of disease progression. We should identify the flat 
urothelial lesions and the papillary tumor growth
Biologic 
behaviour
The tumor should grow intravesical, so that the tumor can 
be directly exposed to intravesical anticancer drugs in its 
natural environment
Natural 
history
Mimic pathogenesis of human urinary bladder cancer, with 
identifiable precursor lesions
Genetic 
alterations
Stable molecular and genetic alterations similar to those 
found in human bladder cancer
Feasibility Simple induction procedure, predictable and adjustable 
incidence
There	are	several	advantages	 to	using	rodents	 in	
medical	 research,	 their	physiology	and	genetics	are	
well	understood,	they	are	relatively	easy	and	cheap	to	
maintain,	and	like	humans,	they	are	mammals.	Rodents	
develop	cancer	relatively	easily	in	response	to	chemical	
carcinogens.	Their	tumors	also	develop	rather	quickly,	
over	months	rather	than	years	[69].	A	major	difference	
may	be	a	lower	rate	of	distant	metastases	in	rats	than	in	
humans,	although	this	is	not	certain	[90].	Metastases	and	
invasions	of	bladder	cancer	are	more	common	in	mice	
than	in	rats.	The	lack	of	metastasis	in	experimental	ani-
mals	may	be	due	to	the	time	factor.	Animals	are	killed	at	
the	end	of	experimental	period,	or	even	earlier,	to	prevent	
suffering	and	for	optimal	tissue	collection,	which	may	be	
too	soon	for	metastases	development	[11].	Concerning	
the	selection	of	animals,	we	may	choose	between	inbred	
or	outbred	strains	of	rodents.	An	important	benefit	of	the	
use	of	inbred	animals	is	that	many	can	be	supplied	which	
develops	virtually	identical	tumors	at	the	same	stage	of	
growth.	However,	an	important	concern	is	the	degree	to	
which	tumor	heterogeneity	may	be	lost	[77].	Since	the	
aim	of	laboratory	animal	experiments	is	to	elucidate	the	
pathological	process	in	humans	as	well	as	to	test	chemi-
cals	for	carcinogenic	potential,	classification	of	animal	
tumors	should	agree	with	 the	nomenclature	used	for	
human	neoplasms	[1].	However,	the	differences	in	their	
histological	appearance,	growth	pattern	and	biological	
behaviour	need	to	be	emphasized	[7].	
induced Tumors 
Yamagiwa	and	Ichikawa	in	1918	where	the	first	to	
proof	 that	cancer	could	be	 induced	 in	experimental	
animals	by	chemical	means	 [98].	The	 induction	of	
bladder	cancer	in	dogs	by	-naphtylamine,	reported	
by	Hueper	in	1938,	established	the	experimental	basis	
of	bladder	carcinogenesis	[40].	Early	attempts	to	in-
duce	tumors	in	mice	bladders	by	means	of	chemicals	
were	unsuccessful	until	Armstrong	and	Bronser	(1944)	
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induced	papillomas	and	carcinomas	through	the	oral	
administration	of	-acetylaminoflourene	(AAF)	in	CBA	
strain	mice	[4].	
In	 the	 1960s	 and	 early	 1970s,	 organospecific	
chemically-defined	bladder	carcinogens	were	discov-
ered	for	rodents.	These	chemicals	and	their	application	
provided	 the	 readily-available	 reproducible	models	
necessary	 for	detailed	studies	of	 the	biochemical,	
pathobiological	and	 immunological	mechanisms	 in-
volved	in	the	pathogenesis	of	bladder	cancer	[18].	
There	are	several	methods	of	 inducing	urothelial	
tumors:	oral	administration	of	a	chemical	carcinogen	
in	diet,	water	or	gastric	intubation	(gavage),	by	injec-
tion	or	 intravesical	 instillation;	 the	application	of	 the	
stimulus	directly	by	implanting	in	the	bladder	a	pellet	
either	by	 itself	or	with	a	chemical	 incorporated	 in	 it;	
and	exposure	to	X-rays.
Chemical carcinogens. As	mentioned	before,	
the	 first	compound	applied	 in	experimental	bladder	
carcinogenesis	was	AAF.	Although	of	considerable	
usefulness	 in	experimental	bladder	carcinogenesis	
research,	 the	AAF	 is	a	pluripotential	carcinogen,	 in-
ducing	 tumors	of	 several	 tissues	 in	addition	 to	 the	
urothelium	particularly	the	liver,	pancreas,	breast,	skin,	
forestomach	and	ear	duct	[4,	18,	1].	Hepatic	tumors	
may	cause	early	death	of	the	animals	and	confusion	in	
the	interpretation	of	the	experimental	results	[79].
Over	the	past	few	decades,	research	efforts	have	
focused	on	 the	development	of	 rodent	models	 that	
permit	the	reproducible	induction	of	bladder	cancer	
with	minimal	or	no	induction	of	tumors	in	other	organs.	
Three	chemicals	have	been	proved	to	be	particularly	
effective,	in	that,	when	administered	via	the	appropri-
ate	route,	at	the	appropriate	dose	and	in	the	appro-
priate	strain	of	animal,	all	produce	100%	incidence	of	
bladder	tumors;	these	chemicals	are	N-[4-(5-nitro--
furyl)--thiazolyl]	formamide	(FANFT),	N-butyl-N-(4-
hydroxybutyl)	nitrosamine	(BBN)	and	N-Methyl-N-ni-
trosurea	(MNU)	[30].	These	compounds	are	complete	
carcinogens,	the	total	dose	has	a	greater	effect	when	
administered	as	several	fractions,	i.e.	the	effect	of	the	
fractions	is	synergistic	rather	than	additive.	The	grade	
of	cellular	atypia	and	the	extent	of	invasion	increase	as	
the	dose	of	carcinogen	increases	as	well	as	when	the	
experimental	period	is	extended	[31,	51].
The	nitrofuran	FANFT	is	highly	specific	to	the	uri-
nary	bladder	in	the	rat,	mouse,	hamster	and	dog.	It	is	
a	genotoxic	compound	and	can	act	as	an	initiator	or	
as	a	promoter.	It	is	metabolically	activated	into	reactive	
electrophiles,	produces	DNA	adducts	and	ultimately	
produces	mutation	[6,	1,	51].	FANFT	is	deformylated	
in	-amino-4-(5-nitro--furyl)	 thiazole	by	 liver	and	
kidney	enzymes	before	excretion	[89].	Tumors	induced	
by	this	compound	are	predominantly	transitional	cell	
carcinoma	(TCC),	with	a	 large	proportion	exhibiting	
squamous	cell	differentiation.	However,	hyperplasia,	
dysplasia	and	CIS	have	also	been	observed	 [6,	51,	
77].	FANFT	is	incorporated	in	the	diet	and	induction	
of	bladder	cancer	 requires	8	 to	11	months	 [6,	9].	
Transplantable	cell	 lines	have	been	developed	 from	
these	FANFT-induced	 tumors,	 the	most	commonly	
used	are	labelled	MBT-	and	AY-7	[96].	However,	the	
use	of	this	compound	presents	safety	concerns	for	the	
researchers	involved	and	the	environment.	
BBN	is	one	of	the	most	suitable	urinary	bladder	car-
cinogens	for	animal	models,	since	its	carcinogenic	po-
tential	is	essentially	limited	to	this	organ	and	is	probably	
the	most	commonly-referenced	experimental	bladder	
carcinogen	[55,	70].	Bladder	tumors	induced	by	BBN	in	
rats	and	mice	resemble	their	human	counterparts	[55].	
BBN	is	a	metabolite	of	the	symmetric	dibutylnitrosamine	
(DBN)	[46].	In	rats,	both	were	demonstrated	to	be	uri-
nary	bladder	carcinogens,	with	BBN	being	specific	to	
the	urinary	bladder,	because	DBN	also	induced	tumors	
of	the	liver,	lung,	kidney	and	oesophagus	[17,	39].	In	
mice,	similar	aspects	have	been	found	[9,	1].	The	dif-
ference	 in	 lesions	histopathology	 identified	between	
different	 rodents	exposed	 to	BBN	can	be	attributed	
to	dosage,	lag	time	until	tumor	development,	species,	
and	strain.	BBN	is	bladder	specific	not	only	in	rats	but	
also	in	mice	and	dogs.	However,	it	 is	a	weak	bladder	
carcinogen	in	hamsters	and	pigs	[51,	69].	A	100%	in-
cidence	of	tumors	can	be	induced	by	continuous	and	
prolonged	administration	of	BBN	in	drinking	water.	This	
compound	can	also	be	administered	by	oral	gavage	
[51].	Subcutaneous	injections	generally	result	in	a	lower	
incidence	of	tumors	[1].	BBN	can	also	be	introduced	
into	the	bladder	by	intravesical	instillation	[95].	BBN	is	
a	yellow	oily	liquid	not	very	volatile	but	is	soluble	due	
to	 terminal	hydroxylation.	When	dissolved	 in	water	
BBN	is	easy	to	apply.	However,	it	is	photosensitive	and	
therefore	an	opaque	feeding-bottle	is	necessary	[55].	
BBN	 is	a	genotoxic	compound.	The	alcoholic	group	
of	administered	BBN	is	rapidly	oxidized	to	a	carboxyl	
group	by	the	liver	enzymatic	system	alcohol/aldehyde	
dehydrogenase;	the	metabolite	formed	by	N-butyl-N-
(3-carboxybutyl)	nitrosamine	(BCPN)	is	also	a	bladder	
carcinogen	and	comes	in	contact	with	the	urothelium	
via	the	urine.	BCPN	is	a	stable	compound	that	binds	
covalently	to	cellular	macromolecules	and	is	ultimately	
responsible	for	the	initiation	of	the	carcinogenic	process	
[1].	BCPN	produces	neoplasic	transformation	of	rat	uro-
thelial	cells	cultured	in vitro	[9].	In	dogs,	the	dosage	of	
BBN	is	related	to	the	grade	of	bladder	cancer	[].	In	low	
dosages,	BBN	causes	low-grade	papillary	carcinoma	
after	long	periods	of	exposure	[77].
N-Ethyl-N-(4-hydroxybutyl)	nitrosamine	(EHBN)	is	
a	genotoxic	compound	even	more	potent	than	BBN.	
It	targets	the	urothelium	of	mice,	rats	and	dogs	[93].	
Hamsters	are	however	less	sensitive	to	this	carcinogen	
and	guinea	pigs	appear	to	be	resistant	[1,	39].	EHBN	
is	metabolized	by	hepatic	enzymes	in	N-ethyl-N-(3-
carboxypropyl)	 nitrosamine	and	excreted	 in	urine.	
In	mice	 this	compound	 increased	 the	 incidence	of	
squamous	cell	 carcinoma	and	 is	a	good	model	 for	
the	 investigation	of	 nonpapillary	 invasive	bladder	
carcinoma.	The	carcinomas	that	develop	demonstrate	
invasion	of	the	surrounding	tissues	and	are	associated	
with	hematogenous	metastic	spread	to	distant	organs	
[93].	Other	nitroso	compounds	such	as	N,	N-dibutil-
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nitrosamine	and	N-methyl-N-dodecylnitrosamine	are	
carcinogenic	to	the	urinary	bladder	in	rats	[51].	
MNU	is	the	only	carcinogen	known	to	act	directly	on	
the	urothelium	following	spontaneous	pH-dependent	
decomposition	without	requiring	metabolic	activation.	
At	present	MNU	is	the	only	urothelial	carcinogen	known	
to	produce	bladder	cancer	at	a	single	dose	[51].	MNU	
is	a	fine	yellowish	crystalline	powder	stabilized	by	addi-
tion	of	5%	acetic	acid	[5].	Because	MNU	is	intrinsically	
unstable,	variations	in	carcinogenic	potency	can	arise	
unless	care	is	taken	during	its	storage,	preparation	and	
use	[51].	It	is	a	genotoxic	compound	that	can	act	as	an	ini-
tiator	or	as	a	promoter	and	cause	persistent	methylation	
of	the	DNA	[53,	57].	The	MNU	model	of	bladder	cancer	
has	particular	advantages	for	the	experimental	analysis	
of	complete	carcinogenesis,	since	the	carcinogen	can	
be	administered	directly	in	quantifiable	pulse	doses,	via	
intravesical	 instillation	[76].	The	disadvantage	of	 this	
procedure	is	that	in	some	animals	bladder	concretions	
and/or	urocystitis	may	develop	[53,	86].	Bladders	treated	
with	 intravesical	MNU	develop	progressive	neoplastic	
changes,	and	 the	 tumors	become	progressively	 less	
differentiated	with	 time.	These	 lesions	progress	 from	
hyperplasia,	atypia,	CIS,	and	papillary	carcinoma	 to	
large	bulky	muscle	invasive	tumors	that	completely	fill	the	
bladder	lumen,	obstruct	the	ureteres	and	kill	the	animal	
[53,	91].	These	tumors	have	a	relatively	 low	potential	
for	metastasis	with	deposits	being	found	in	abdominal	
lymph	nodes	and	within	the	abdominal	cavity	[7].	MNU	
also	causes	local	massive	inflammation	of	the	bladder	
mucosa	and	submucosa	and	infiltration	of	the	bladder	
wall	with	acute	inflammatory	cells	and	exudates	[4].
4-Ethylsulfonylnaphthalene-1-sulfonamide	(ENS)	
is	a	carbonic	anhydrase	inhibitor	that	produces	alka-
line,	hypoosmolar	urine	with	crystalluria	and	calculi	
formation.	Urinary	tract	hyperplasia	occurred	in	mice	
fed	ENS	at	a	dose	of	0.1%	of	their	diet	[1].
Benzidine,	3,	3´-dichlorobenzidine,	-naphthyl-
amine,	 4-aminobiphenyl,	 -acetylaminofluorene,	
phenacetin,	 and	sodium	ο-phenylphenate	are	ad-
ditional	compounds	which	are	carcinogenic	 for	 the	
urinary	bladder	[86].	
Bracken	fern	(Pteridium aquilinum)	induces	upper	ali-
mentary	tract	and	bladder	cancer	in	a	number	of	species	
including	rats,	guinea	pigs	and	cows	[1,	81].	The	major	
carcinogenic	compound	of	bracken	fern	is	ptaquiloside,	
a	non-sesquiterpene	that	alkylates	DNA	when	metabo-
lized	into	an	unstable	dienone	under	alkaline	conditions	
[87].	Ptaquiloside	accumulates	in	the	body	of	rats	arti-
ficially	fed	bracken	fern	and	is	eliminated	in	urine	where	
its	carcinogenic	activity	is	preserved	[75].
In	Table	,	we	show	the	results	of	several	studies	
with	different	carcinogens,	treatments,	animals	used	
and	lesions	identified.
Using	bladder	cancer	models,	several	compounds	
have	been	evaluated	as	suitable	for	intravesical	thera-
py	(chemotherapy	and	immunotherapy)	and	systemic	
chemotherapy	[64,	66,	88,	91].	More	recently	photo-
dynamic	therapy	with	hypericin	and	protoporphyrin	IX	
was	also	investigated	[97].	
Pellet implantation and urinary calculi. The	pres-
ence	of	foreign	bodies	within	the	lumen	of	the	bladder	
can	cause	irritation	or	trauma	to	the	urothelium,	both	
stimulate	mitotic	activity,	thereby	causing	nodular	and	
papillary	hyperplasia	[4,	7].	Mitotic	activity	predis-
poses	cells	to	the	action	of	both	initiating	and	promoting	
substances	[4].	If	there	is	extensive	ulceration	of	the	
bladder	surface,	diffuse	papillomatosis	 is	produced	
[0].	Although	direct	 implantation	of	pellets	contain-
ing	suspected	carcinogens	was	attempted	in	194,	it	
wasn’t	until	1951	when	Jull	successfully	induced	blad-
der	tumors	by	this	method	[47].	This	technique	involves	
surgical	 implantation	of	pellets	 into	 the	 lumen	of	 the	
rodent	bladder.	The	materials	used	as	the	basis	for	the	
pellets	were	paraffin	or	cholesterol	and	it	was	thought	
that	these	materials	remained	biologically	inert	in	the	
bladder	lumen.	Various	chemicals	were	incorporated	
into	these	pellets	for	implantation	into	the	bladder	lu-
men.	It	was	assumed	that	the	bladder	epithelium	was	
incapable	of	metabolizing	these	chemicals,	so	that	the	
introduced	chemical	represented	the	ultimate	form	of	
the	carcinogen	[15].	It	was	also	assumed	that	the	pellet	
itself	did	not	pose	a	carcinogenic	risk	to	the	urothelium	
[47].	In	1979	Jull	demonstrated	in	an	experiment	that	
the	pellets	inserted	into	the	mouse	bladder	itself	repre-
sented	a	carcinogenic	risk	[48].	In	addition,	it	became	
apparent	 that	 the	urothelium	 is	metabolically	active,	
through	evidence	of	the	activities	of	enzymes	involved	
in	 the	metabolism	of	exogenous	and	endogenous	
chemicals	[3].	Urine	was	required	as	a	co-factor	for	the	
carcinogenic	effect	of	the	pellet	[13].	The	rapidity	with	
which	the	chemical	was	leached	from	the	pellet	varied	
considerably,	depending	on	 the	solubility.	For	highly	
water-soluble	compounds	such	as	saccharin	and	cycla-
mate,	the	chemical	was	rapidly	leached	from	the	pellet	
[1].	In	addition,	the	surgical	procedure,	to	implant	the	
pellet,	produced	nodular	and	papillary	hyperplasia	[3].	
This	method	has	since	been	abandoned,	because	these	
problems	made	the	interpretation	of	the	results	utilizing	
the	pellet	implantation	technique	difficult	[0].
During	the	past	three	decades,	numerous	chemicals	
have	been	identified	as	producing	bladder	tumors	in	ro-
dents	and	are	associated	with	the	appearance	of	urinary	
calculi	[16].	Such	chemicals	 include	uric	acid,	calcium	
oxalate,	uracil,	thymine,	melamine,	and	others	[34,	85].	Of	
these	compounds,	uracil	is	the	most	widely	applied	[67].	In	
the	rat	urinary	bladder,	uracil	is	reported	to	induce	calculi	
and	papillomatosis	when	administered	in	the	diet	[56,	84].	
The	proliferative	effects	of	calculi	are	commonly	sustained	
in	rodents	since	these	species	are	normally	horizontally	
positioned	allowing	the	object	to	remain	within	the	lumen	
of	the	urinary	bladder,	with	less	chance	of	elimination	[4].	
If	the	calculus	is	removed	before	a	neoplasm	is	produced,	
the	proliferative	changes	are	rapidly	reversed.	Urinary	tract	
calculi	represent	foreign	bodies,	similar	to	pellets,	but	do	
not	require	surgical	implantation	into	the	bladder	lumen	
[16,	0,	3].	The	calculi	can	arise	from	the	administered	
chemical	 itself,	 from	one	of	 its	metabolites	or	from	an	
endogenous	metabolic	product	that	is	caused	by	the	ad-
ministration	of	the	chemical.	In	general,	calculi	form	more	
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quickly	in	rats	than	in	mice.	Calculi-induced	proliferation	
appears	to	be	considerably	greater	in	rats	than	in	mice.	
This	difference	is	particularly	due	to	a	primary	papilloma-
tous	reaction	in	rats,	whereas	in	mice	it	is	predominantly	a	
nodular	response	[3].	There	is	also	a	difference	between	
sexes;	male	rodents	are	more	frequently	affected	than	
females	[4].	The	process	involved	in	urothelial	carcino-
genesis	related	to	calculus	formation	may	be	influenced	
by	factors	such	as	pH,	volume,	osmolality,	cationic	and	
anionic	concentration	and	quantitative	and	qualitative	
differences	in	the	presence	of	urinary	protein	[16].
Calculi	can	be	surgically	produced	in	rats	by	per-
forming	a	portacaval	shunt,	which	leads	to	significant	
alteration	of	uric	acid	metabolism	and	eventual	pro-
duction	of	uric	acid	calculi,	ulceration,	 regenerative	
proliferation,	and	carcinoma	[6,	45].
Promoting agents. Multistage	models	of	carci-
nogenesis	proposed	to	explain	 the	patterns	of	 tumor	
development	observed	in	the	urinary	bladder	involve	the	
initiation	of	neoplastic	change	in	a	few	cells	by	a	threshold	
dose	of	carcinogen	followed	by	conversion	of	these	latent	
tumor	cells	into	an	autonomous	cancer	by	further	doses	
of	the	same	and/other	carcinogens,	and/or	promoting	
agents.	In	the	urinary	bladder	of	mice	and	rats,	neoplastic	
change	can	be	initiated	by	a	few	weeks	treatment	with	
low	doses	of	chemical	carcinogens	above	described.	
Animals	exposed	subsequently	to	promoter	compounds	
will	develop	bladder	cancer	[33,	73].
Urinary	bladder	promoters	can	be	classified	 into	
at	 least	seven	categories	as	 follows:	1)	sodium	and	
potassium	salts	associated	with	 increased	concen-
tration	of	urinary	levels	of	sodium	and	potassium	ions	
and	alkaline	urine;	)	urolithiasis	 inducing	agents;	
3)	antioxidants;	4)	anticancer	drugs;	5)	amino	acids;	
6)	drugs	and	others	[31,	43].	Table	3	shows	the	clas-
sification	of	bladder	cancer	promoters.	
Irradiation. Treatments	with	 ionizing	 radiation	
have	been	shown	to	cause	bladder	cancer	in	humans.	
Irradiation	with	X-rays	is	capable	of	inducing	preneo-
plastic	 urothelial	 hyperplasia	 and	development	of	
urothelial	carcinoma	 in	rodents.	The	rate	of	bladder	
tumors	achieved	with	irradiation	depends	on	the	dos-
age	time	of	exposure	and	time	of	follow	up.	A	single	
dose	of	irradiation	generated	from	a	linear	accelerator	
induced	hyperplasia	of	the	urothelium	when	mice	were	
examined	3–19	months	later	[50,	9].
Table 3. Classification of urinary bladder cancer promoters
Type Cancer promotor
Sodium or potassium 
salts
Sodium saccharin
Sodium cyclamate
Sodium L-ascorbate
Sodium citrate
Sodium erithorbate
Sodium phenobarbital
Sodium barbital
Sodium chloride
Potassium carbonate with or without ascorbic acid
Urolithiasis-inducing 
chemicals
Uracil
Diphenyl
Antioxidants Butylated hydroxyanisole
Butylated hydroxytoluene
Ethoxyquin
t-Butylhydroxyquinone
2-t-Butyl-4-methylphenol
Anticancer drugs Adriamycin
Mitomycin C
Amino acids DL-Tryptophan
L-Leucine
L-Isoleucine
Drugs Phenacetin
Others Components of urine
Allopurinol
Dimethylarsinic acid
Table 2. Chemically induced bladder tumors
Agent Treatment Host Tumor type
Bracken 
Fern
Dietary [75] Albino rats (♂ and ♀) Hyperplasia, TCC, invasion.
BBN 0.05% in water, 40 w (weeks) [61] ACI rats ♂ (6w) 1 w no lesions, 2 w hyperplasia, 4 and 12 w papilloma, 20 w TCC
0.05%; 0.01% and 0.005% in water, 
4, 8, 12, 16, 20, 26 w [68]
C3H/He ♀ mice (5w) 0.05% BBN 4 w and 8 w simple hyperplasia and dysplasia; 12, 16, 20 and 26 w 
simple hyperplasia, dysplasia, CIS, invasive carcinoma.
0.01%BBN 4 w simple hyperplasia; 8, 12, 16 w simple hyperplasia and dysplasia; 
20 and 26w simple hyperplasia, dysplasia, CIS and invasive carcinoma.
0.005% BBN 4 w no lesions; 8 and 12 w simple hyperplasia, 16 and 20 w simple 
hyperplasia and dysplasia; 26 w simple hyperplasia, dysplasia, CIS and invasive 
carcinoma.
50 or 100 mg gastric intubations, 
2 x w, 9 w [6]
B6D2F1, mice ♂ TCC, SCC, Adenocarcinoma
0.05% water, 20 w [32] Wistar rats ♂ Hyperplasia, TCC, papillary tumors
0.05% water (16 w and 32 w) [60] Fisher 344 rats ♂ 
(6 w)
16 w and 32 w TCC
Gavage (3 fractionated doses at 24h 
intervals, BBN dissolved in 1:2 pro-
pandiol 300 mg/Kg BW) [54]
Wistar rats ♀ 19 months later: Papillomas and invasive TCC 
EHBN 0.025% water (4 w, 12 w, 20 w, 
28 w, 36 w) [93].
B6C3F1 mice ♂ (6 w) 4w-dysplasia; 12w, 20w, 28w and 36w-dysplasia, papiloma, TCC, SCC, adenocar-
cinoma, CIS; metastasis
0.05% water 32 w [44] B6C3F1 mice ♂ (6 w) TCC (invasive), SCC
FANFT Dietary: 0.1% (45 w) [65] C3H/He mice ♀ (6 w) Dysplasia, CIS and TCC
Dietary 0.02% [22] Fisher 344 rats ♂ 
(4 w)
Hyperplasia (6 w)
Nodular hyperplasia (8 w)
Papillary tumours (10,12,14 w)
Dietary: 0.1% (38w) [63] C3H/He mice ♀ (6 w) Dysplasia, CIS and TCC
MNU Intravesical 5 mg/Kg BW [52] Wistar rats ♀ 15 months latter exophytic papiloma and invasive TCC
1.5 mg every 2 weeks (x 4), intra-
vesical [91]
Fisher 344 rats ♀ Hyperplasia, papillary lesions, squamous metaplasia
0.15 ml intravesical, 4 doses 
over 6 weeks [76]
Fisher 344 rats ♀ 10 weeks after last treatment TCC
Notes: w — weeks; x — times; TCC — transitional cell carcinoma; SCC — squamous cell carcinoma; CIS — carcinoma in situ, BW — body weight; ♂ — male; ♀ — female
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cell culTure
Cell	culture	represents	an	excellent	opportunity	to	
study	bladder	cancer	in vitro.	The	growth	of	normal	and	
neoplasic	urothelial	cells,	obtained	from	rodents,	or	
man,	in	tissue	culture,	offers	the	possibility	of	studying	
“pure”	populations	of	cells	without	necessarily	having	
significant	contamination	by	other	tissues	[77].	Differ-
ent	methods	for	the	culture	of	urothelial	cells	in vitro	
are	described:	 the	propagation	of	primary	cultures	
and	cell	lines	derived	from	normal	urothelial	cells	ex-
posed	to	chemical	carcinogens	and	continuous	cell	
lines	derived	from	bladder	tumors	[59].	Such	cultures	
provide	model	systems	for	studying	the	factors	that	
control	the	growth	and	differentiation	of	both	normal	
and	neoplastic	urothelial	cells,	and	 for	defining	 the	
morphological,	 biochemical	 and	genetic	 changes	
associated	with	the	development	and	progression	of	
bladder	cancer	[58,	59].	Furthermore,	they	provide	the	
opportunity	to	observe	the	evolution	of	cancer	within	
a	population	of	cells	exposed	to	a	carcinogen	and	to	
study	the	effectiveness	of	anticancer	drugs	[58,	77,	
8].	Cell	cultures	also	offer	the	opportunity	to	study	the	
chromosomal	changes	associated	with	early	develop-
ment	of	bladder	cancer.
Tumor implanTaTion 
As	we	described	before,	bladder	 tumors	can	be	
induced	in	rodents	using	a	variety	of	chemicals.	How-
ever,	these	tumors	required	8–1	months	to	develop,	
they	grew	very	slowly	and	many	animals	are	required	
[43,	6,	96].	While	 induction	of	bladder	 tumors	 in	
animals	by	chemical	means	has	allowed	the	study	of	
carcinogenesis	and,	in	some	cases,	chemotherapeutic	
agents,	the	majority	of	research	leading	towards	clini-
cal	applications	requires	models	based	upon	human	
cancer	cells	[41].
Currently	there	are	two	more	fundamental	murine	
bladder	 tumor	models:	 the	xenograft	model	 (trans-
plantation	of	 human	urothelial	 cell	 carcinoma	 into	
immunodeficient	mice)	 [41,	80],	and	 the	syngeneic	
model	(transplantation	of	carcinogen-induced	blad-
der	cancer	in	syngeneic,	i.e.	immunocompetent	mice)	
[78,	88].	Syngeneic	 tumor	cells	 can	be	 implanted	
subcutaneously	 (heterotopic)	 [4]	or	 intravesically	
(orthotopic)	[37].	
For	 reasons	of	easy	access,	heterotopic	models	
(subcutaneous,	 intravenous	 and	 intraperitoneal)	
have	been	preferred	 for	human	tumor	 implantation.	
However,	it	is	questionable	if	the	tumor	development	
at	these	sites	parallels	the	development	of	the	tumor	
in	the	organ	of	its	origin	[4].
Orthotopic	 tumor	 implantation	 is	more	difficult.	
However,	 the	 refinement	of	 the	various	methods	of	
orthotopic	 implantation	now	allows	 this	 system	 to	
be	used	 routinely	 for	a	 variety	of	applications.	This	
model	 of	 bladder	 cancer	 allows	 the	 growth	 and	
spread	of	bladder	cancer	to	be	better	observed	in	a	
normal	physiologic	environment	and	permits	novel	
approaches	 to	cancer	 therapy	or	 imaging	of	 tumor	
growth.	The	tumor	cells	used	for	intravesical	instillation	
may	be	obtained	from	urothelial	cell	cultures	exposed	
to	chemical	carcinogens	(MBT-	and	AY-7)	or	human	
bladder	neoplasic	cells	may	be	used	(MGH-U3)	[96].	
Cells	can	be	introduced	into	the	bladder	cavity	after	
chemical	urothelial	denudation	(leading	to	multifocal	
lesions)	or	after	mechanical	urothelial	lesion	(requir-
ing	cystotomy)	[8,	4].	The	first	method	is	less	time-
consuming,	requires	no	surgery	and	does	not	bring	
up	diffuse	ulceration,	oedema	or	urinary	stones.	 Its	
tumor	 implantation	success	 rate	 ranges	 from	8	 to	
97%.	The	tumors	are	multifocal	and	their	localization	
is	unpredictable	 [8].	Transplantable	animal	models	
are	not	technically	complicated,	are	well	tolerated	by	
the	animals	and	result	in	minimal	morbidity	associated	
with	occasional	haematuria	subsequent	to	tumor	cell	
instillation	 [4,	96].	More	 importantly	 is	 that	 these	
tumors	are	produced	intravesically	and	arise	from	the	
urothelium.	Consequently,	the	tumor	can	be	directly	
exposed	to	intravesical	anticancer	drugs	in	its	natural	
environment	[49].	However,	this	model	is	not	perfect.	
Its	one	disadvantage	 is	 that	 the	 tumors	prove	 to	be	
invasive	carcinomas	from	the	start;	this	 is	related	to	
the	mechanical	urothelial	abrasion	[8].	
Transgenic models For bladder 
cancer
Genetically	 engineered	animals,	 usually	 trans-
genic	or	gene	targeted	mice,	allow	the	examination	
of	whether	genetic	changes,	including	oncogene	over	
expression/mutation	or	tumor	suppressor	gene	loss,	
can	increase	the	risk	of	neoplasic	progression;	whether	
genetic	changes	can	cooperate	during	bladder	car-
cinogenesis;	and	how	the	genetic	signature	of	a	neo-
plasm	correlates	with	particular	biological	aspects	of	
tumor	development	[36].	Transgenic	mice	carrying	the	
human	C-Ha-ras	proto-oncogene,	v-Ha-ras	transgenic	
mice,	pim-1	 transgenic	mice,	and	several	knockout	
strains	of	mice	deficient	 in	tumor	suppressor	genes	
such	as	p53	 have	been	shown	 to	exhibit	 increased	
carcinogen	susceptibility	[35].	p53	knockout	mice	are	
much	more	sensitive	to	BBN	urinary	bladder	carcino-
genesis	than	the	parental	mice	strain	C57Bl/6	[74,	99].	
For	studies	of	chemical	carcinogenesis	rats	are	gen-
erally	more	frequently	used	than	mice.	However,	only	
limited	types	of	transgenic	rats	have	been	developed	
for	studying	carcinogenesis.	The	establishment	of	a	
rat	model	with	similarities	may	be	the	ideal	solution.	A	
transgenic	rat	line	carrying	three	copies	of	the	human	
c-Ha-ras	proto-oncogene	was	developed	with	its	own	
original	promotor	region.	This	rat	is	highly	susceptible	
to	BBN	carcinogenesis	and	may	be	utilized	as	a	 rat	
model	for	analysis	of	bladder	tumor	development	[71].	
Tsuda	et	al.	[95]	concentrated	their	attention	on	the	
generation	of	 transgenic	 rats	with	 the	same	human	
c-Ha-ras	proto-oncogene	used	for	the	establishment	
of	transgenic	mice.	The	rat	line	developed	by	this	team	
called	Hras18	is	highly	susceptible	to	BBN	bladder	
carcinogenesis	[94].	Table	4	shows	the	utility	of	each	
model	in	function	of	the	subject	to	be	studied	[77].
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Table 4. Utility of different models to study bladder cancer
Subject for study
Tumors 
chemically 
induced
Cell cul-
tures
Tumor im-
plantation
Transgenic 
models
Conventional histology yes no yes yes
Ultraestructure yes yes yes yes
Immunohistochemical yes yes yes yes
Histochemical yes no yes yes
Molecular genetics and 
proteomics
yes yes yes yes
Image cytometry yes yes yes yes
Image analysis yes yes yes yes
Treatment yes? yes? yes yes?
Kinetics yes yes? yes yes
Carcinogenesis yes yes no yes
Note: ? — not fully validated.
evaluaTion oF neoplasic 
developmenT in rodenTs
Urinary	cytology	has	been	useful	 in	the	diagnosis	
and	 intermittent	observation	of	patients	with	urinary	
bladder	carcinoma.	Surprisingly,	urinary	cytology	has	
received	little	study	in	rodents.	Confirmation	of	tumor	
development	and	therapeutic	effects	in	rodents	is	made	
possible	by	 the	detection	of	a	palpable	suprapubic	
mass,	gross	haematuria,	weight	 loss	or	when	 lapa-
rotomy	or	cystectomy	is	performed	[8].	However,	these	
techniques	do	not	have	reliable	parameters	which	en-
able	the	tumor	growth	to	be	assessed.	Only	large	tumors	
(>	00	mg)	are	clearly	detected	by	abdominal	palpation	
[38].	To	solve	this	limitation	non-invasive	diagnosis	of	
superficial	bladder	tumors	in	animals	can	be	applied.	
It	is	possible	to	detect	and	follow	the	development	of	
induced	bladder	tumors	using	ultrasonography,	a	non-
invasive	imaging	technique	that	accurately	estimates	
tumors’	morphologic	characteristics	[3,	8].	Magnetic	
resonance	has	also	been	reported	for	this	purpose	[96].	
However,	due	to	the	spatial	resolution	of	magnetic	reso-
nance	imaging	accurate	diagnosis	of	small	early	lesions	
could	not	be	obtained.	The	use	of	the	non	invasive	ultra	
thin	endoscope,	developed	by	Asanuma	et	al.	[5]	allows	
the	detection	of	bladder	tumors	with	a	minimal	lesion	of	
1	mm.	Cytoscopic	examination	is	a	reliable	noninvasive	
method	for	detecting	and	monitoring	superficial	tumors	
[5].	All	methods	described	above	proved	to	be	suitable	
means	of	monitoring	intravesical	growth,	but	each	ima-
ging	procedure	required	anaesthesia	and	catheteriza-
tion.	Almost	0%	of	the	animals	died	prior	to	the	end	of	
the	study	due	to	procedural	mishaps	[3].
conclusion
We	have	reviewed	experimental	data	related	to	the	
induction	of	bladder	cancer	in	rodents.	Our	intention	is	
not	to	propose	any	specific	model	for	researching	blad-
der	cancer	but	to	give	enough	information	to	develop	a	
framework	in	each	instance	to	encourage	questioning	
of	the	process.	Multiple	experimental	approaches	have	
been	employed	to	study	bladder	cancer,	including	the	
use	of	rodents.	Rodents	have	the	advantage	that	they	
can	be	manipulated	 to	address	specific	hypotheses	
concerning	the	mechanisms	underlying	this	disease.	
However,	it	should	not	be	forgotten	that	the	direct	study	
of	human	bladder	cancer	continues	to	be	vitally	impor-
tant	 in	understanding	 the	biology	of	bladder	cancer.	
In	the	human	bladder,	it	is	likely	that	the	urothelium	is	
chronically	exposed	to	sub-cytotoxic	doses	of	genotox-
ins	and,	consequently,	acute	exposure	may	not	be	rep-
resentative	of	the	process	in	man.	Each	rodent	model	
to	study	bladder	carcinogenesis	has	strong	and	weak	
points.	The	one	that	is	most	suitable	for	the	purpose	of	
each	study	must	be	selected.	The	rodent	urinary	blad-
der	is	very	similar	to	the	human	urinary	bladder,	which	
helps	 to	understand	bladder	carcinogenesis.	Like	 in	
humans,	the	spectrum	of	lesions	observed	in	urinary	
bladder	in	mice	and	rats	include	preneoplastic	lesions,	
papillary	tumors	and	invasive	carcinoma.	The	selection	
between	mice	and	rats	may	be	based	on	the	aims	of	the	
study.	For	instance,	the	small	bladder	size	of	mice	limits	
both	histologic	characterization	and	the	application	of	
intravesical	therapeutics.
Chemical	 induction	of	bladder	cancer	 in	rodents	
usually	requires	8–1	months.	However,	the	adminis-
tration	of	chemicals	in	water	or	diet	although	effective	
present	inherent	risks	to	the	safety	of	laboratory	per-
sonnel.	Moreover,	it	is	difficult	to	quantify	the	amount	
of	carcinogen	ingested	by	each	animal.	This	disadvan-
tage	of	carcinogen	dosing	may	be	eliminated	by	the	
administration	of	the	carcinogen	via	gavage.	
Transgenic	rodent	models	of	bladder	cancer	also	
have	both	advantages	and	disadvantages.	Since	all	
feature	a	specific	transgene	and	the	latent	period	of	
cancer	development	 is	 relatively	short,	 they	should	
provide	useful	 tools	 for	analysing	 the	 fundamental	
biology	and	roles	of	specific	genes	in	tumor	develop-
ment	and	progression.
By	monitoring	the	responses	to	chemical	carcino-
gens	using	experimental	models,	it	has	been	possible	
to	 identify	many	of	 the	mechanisms	 through	which	
tumors	developed.	Animal	tumors	also	provide	an	op-
portunity	to	study	the	chromosomal	changes	associ-
ated	with	the	early	development	of	bladder	cancer.	In	
addition,	such	studies	may	establish	whether	different	
carcinogens	are	associated	with	specific	cytogenetic	
abnormalities,	hence	defining	 the	specific	gene(s)	
involved	in	the	development	of	bladder	cancer.	Finally,	
with	 the	progress	 in	 the	development	of	 the	rat	and	
mouse	genome	programs,	without	difficult	 ethical	
problems	and	with	much	shorter	generations,	as	yet	
undescribed	genes	related	to	cancer	development	in	
human	cases	should	be	successfully	detected.
acknowledgemenTs
This	study	was	supported	by	a	Grant-in-Aid	from	
the	Fundação	para	a	Ciência	e	Tecnologia,	Ministério	
da	Ciência	e	Ensino	Superior,	Portugal,	with	the	num-
ber	1453/003.
reFerences
1. Airoldi L, Magagnotti C, Bonfanti M, Fanelli R. Alpha-
oxidative metabolism of the bladder carcinogens N-nitroso-
butyl(4-hydroxybutyl)amine and N-nitrosobutyl(3-carboxy-
propyl) amine within the rat isolated bladder. Carcinogenesis 
1990; 11: 1437–40. 
2. Akagi G, Akagi A, Kimura M, Otsuka H. Comparison of 
bladder tumors induced in rats and mice with N-butyl-N-(4-
hydroxybutyl) nitrosoamine. Gan 1973; 64: 331–6. 
Experimental	Oncology	8,	–11,	006	(March)	 9
3. Alexander B, Makar AA, Hopster D, O’Donnell, PJ, Copt-
coat MJ, Muir G. Development of bladder urothelial hyperplasia 
and carcinoma in portacaval shunted rats is not dependent upon 
urolithiasis. Exp Mol Pathol 2004; 77: 205–59. 
4. Armstrong EC, Bonser GM. Epithelial tumours of the 
urinary bladder in mice induced by 2-acetylamino-fluorine. 
J Pathol 1944; 6: 506–12. 
5. Asanuma H, Arai T, Seguchi K, Kawauchi S, Satoh H, 
Kikuchi M, Murai M. Successful diagnosis of orthotopic rat 
superficial bladder tumor model by ultrathin cystoscopy. J Urol 
2003; 169: 718–20. 
6. Becci PJ, Thompson HJ, Strum JM, Brown CC, Spor MB, 
Moon RC. N-butyl-N-(4-hydroxybutyl)nitrosamine-induced 
urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a 
useful model for study of chemoprevention of cancer with 
retinoids. Cancer Res 1981; 41: 927–32. 
7. Bertram JS, Craig AW. Specific induction of bladder 
cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and 
the effects of hormonal modifications on the sex difference 
in response. Eur J Cancer 1972; 8: 587–94. 
8. Bisson JF, Christophe M, Padilla-Ybarra JJ, Notter D, 
Vigneron C, Guillemin F. Determination of the maximal tu-
mor: normal bladder ratio after i.p. or bladder administration 
of 5-aminolevulinic acid in Fischer 344 rats by fluorescence 
spectroscopy in situ. Anticancer Drugs 2002; 13: 851–7. 
9. Bonfanti M, Magagnotti C, Bonati M, Fanelli R, Airoldi L. 
Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-
hydroxybutyl) amine in rats. Cancer Res 1988; 48: 3666–9. 
10. Boorman GA. Animal model of human disease: carcinoma 
of the ureter and urinary bladder. Am J Pathol 1977; 88: 251–4. 
11. Boorman GA, Wood M, Fukushima S. Tumours of the 
urinary bladder. IARC Sci Publ 1994; 111: 383–406. 
12. Bryan GT. Pellet implantation studies of carcinogenic 
compounds. J Natl Cancer Inst 1969; 43: 255–61. 
13. Chapman WH, Kirchheim D, McRoberts JW. Effect of 
the urine and calculus formation on the incidence of bladder 
tumors in rats implanted with paraffin wax pellets. Cancer Res 
1973; 33: 1225–9. 
14. Clayson DB. Editorial: bladder carcinogenesis in rats 
and mice: possibility of artifacts. J Natl Cancer Inst 1974; 52: 
1685–9. 
15. Clayson DB, Cooper EH. Cancer of the urinary tract.  
Adv Cancer Res 1970; 13: 271–381. 
16. Clayson DB, Fishbein L, Cohen SM. Effects of stones 
and other physical factors on the induction of rodent bladder 
cancer. Food Chem Toxicol 1995; 33: 771–84. 
17. Cohen AE, Weisburger EK, Weisburger JH, Ward 
JM, Putnam CL. Cystoscopy of chemically induced bladder 
neoplasms in rabbits administered the carcinogen dibutylni-
trosamine. Invest Urol 1975; 12: 262–6. 
18. Cohen SM. Cell proliferation and carcinogenesis. Drug 
Metab Rev 1998; 30: 339–57. 
19. Cohen SM. Urinary bladder carcinogenesis. Toxicol 
Pathol 1998; 26: 121–7. 
20. Cohen SM. Comparative pathology of proliferative le-
sions of the urinary bladder. Toxicol Pathol 2002; 30: 663–71. 
21. Cohen SM, Friedell GH. In: The mouse in biomedical 
research. Neoplasms of the urinary system. Chapter 24. New 
York: Academic press, 1982: 439–63.
22. Cohen SM, Jacobs JB, Arai M, Johansson S, Friedell GH. 
Early lesions in experimental bladder cancer: experimental design 
and light microscopic findings. Cancer Res 1976; 36: 2508–11. 
23. Cohen SM, Lawson TA. Rodent bladder tumors do not 
always predict for humans. Cancer Lett 1995; 93: 9–16. 
24. DeSesso JM. Confounding factors in direct bladder 
exposure studies. Comments Toxicol 1989; 3: 317–34.
25. DeSesso JM. Anatomical relationships of urinary 
bladders compared: their potential role in the development 
of bladder tumours in humans and rats. Food Chem Toxicol 
1995; 33: 705–14. 
26. Duy N, Yanaguchi Y, Prabhudescri M, Babb J, 
Gans H. Cancer of the bladder in the portacaval shunted rat. 
Gastrenterology 1981; 80: 1331–6. 
27. Dybing E, Sanner T. Species differences in chemical 
carcinogenesis of the thyroid gland, kidney and urinary blad-
der. IARC Sci Publ 1999; 147: 15–32. 
28. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The 
World Health Organization/International Society of Urological 
Pathology consensus classification of urothelial (transitional 
cell) neoplasms of the urinary bladder. Bladder Consensus Con-
ference Committee. Am J Surg Pathol 1998; 22: 1435–48. 
29. Erturk E, Cohen SM, Bryan GT. Induction, histo-
genesis, and isotransplanta bility of renal tumors induced by 
formic acid 2-[4-(5-nitro-2-furyl)-2-triazolyl]-hydrazide in 
rats. Cancer Res 1970; 30: 2098–106. 
30. Frith CH, Eighmy JJ, Fukushima S, Cohen SM, 
Squire RA, Chandra M. In: Guide for Toxicol Pathol. Prolif-
erative lesions of the lower urinary tract in rats. Washington: 
STP/ARP/AFIP, 1995: 1–13. 
31. Fukushima S. Modification of tumor development in 
the urinary bladder. Prog Exp Tumor Res 1991; 33: 154–74. 
32. Fukushima S, Friedell GH, Jacobs JB, Cohen SM. 
Effect of L-tryptophan and sodium saccharin on urinary 
tract carcinogenesis initiated by N-[4-(5-nitro-2-furyl)-2-
thiazolyl]formamide. Cancer Res 1981; 41: 3100–3. 
33. Fukushima S, Imaida K, Sakata T, Okamura T, 
Shibata  M, Ito N. Promoting effects of sodium L-ascorbate 
on two-stage urinary bladder carcinogenesis in rats. Cancer 
Res 1983; 43: 4454–7. 
34. Fukushima S, Murai T. Calculi, precipitates and mi-
crocrystalluria associated with irritation and cell proliferation 
as a mechanism of urinary bladder carcinogenesis in rats and 
mice. IARC Sci Publ 1999; 147: 159–74. 
35. Gollapudi BB, Stott WT, Yano BL, Bus JS. Mode 
of action considerations in the use of transgenic animals for 
mutagenicity and carcinogenicity evaluations. Toxicol Lett 
1998; 102–103: 479–84.
36. Grippo PJ, Sandgren EP. Modeling pancreatic cancer 
in animals to address specific hypothesis. Meth Mol Med 
2005; 103: 217–43. 
37. Gunther JH, Jurczok A, Wulf T, Brandau S, Deinert I, 
Jocham D, Bohle A. Optimizing syngeneic orthotopic murine 
bladder cancer (MB49). Cancer Res 1999; 59: 2834–7. 
38. Gunther JH, Frambach M, Deinert I, Brandau S, 
Jocham D, Bohle A. Effects of acetylic salicylic acid and pentoxi-
fylline on the efficacy of intravesical BCG therapy in orthotopic 
murine bladder cancer (MB49). J Urol 1999; 161: 1702–6. 
39. Hirose M, Fukushima S, Hananouchi M, Shirai T, 
Ogiso  T. Different susceptibilities of the urinary bladder epi-
thelium of animal species to three nitroso compounds. Gan 
1976; 67: 175–89. 
40. Hueper WC. Aniline tumors of the bladder. Arch Pathol 
1938; 25: 858. 
41. Huland H, Otto U, von Paleske A. Chemotherapy and 
human bladder carcinoma transplanted into NMRI nu/nu 
mice. J Urol 1985; 134: 601–6. 
42. Ibrahiem EH, Nigam VN, Brailovsky CA, Madarnas P, 
Elhilali M. Orthotopic implantation of primary N-[4-(5-Ni-
tro-2-furyl)-2-thiazolyl] formamide-induced bladder cancer 
in bladder submucosa: an animal model for bladder cancer 
study. Cancer Res 1983; 43: 617–22. 
10	 Experimental	Oncology	8,	–11,	006	(March)
43. Ito N, Fukushima S. Promotion of urinary bladder carci-
nogenesis in experimental animals. Exp Pathol 1989; 36: 1–15. 
44. Iwata H, Otoshi T, Takada N, Murai T, Tamano S, 
Watanabe T, Katsura Y, Fukushima S. Validation of silver-
stained nucleolar organizer regions for evaluation of invasive 
character of  urinary bladder carcinoma in rats and mice. Urol 
Res 1995; 23: 27–32. 
45. Jaffe V, Alexander B, Price AB, Zanelli GD. The in-
duction of bladder cancer in portally diverted rats. Br J Cancer 
1992; 66: 470–3. 
46. Janzowski C, Jacob D, Henn I, Zankl H, Poole-Zo-
bel BL, Eisenbrand G. Investigations on organ-specific me-
tabolism and genotoxic effects of the urinary N-nitrosodibu-
tylamine (NDBA) and N-nitrosobutyl-4-hydroxybutylamine 
(4-OH-NDBA). Toxicology 1989; 59: 195–209. 
47. Jull JW. The induction of tumours of the bladder 
epithelium in mice by the direct application of a carcinogen. 
Br J Cancer 1951; 5: 328–30. 
48. Jull JW. The effect of time on the incidence of carcino-
mas obtained by the implantation of paraffin wax pellets into 
mouse bladder. Cancer Lett 1979; 6: 21–5. 
49. Kamuhabwa AA, Cosserat-Gerardin I, Didelon J, 
Notter D, Guillemin F, Roskams T, D’Hallewin MA, Baert L, 
de Witte PA. Biodistribution of hypericin in orthotopic 
transitional cell carcinoma bladder tumors: implication for 
whole bladder wall photodynamic therapy. Int J Cancer 2002; 
97: 253–60. 
50. Kunze E. Hyperplasia urinary bladder rat. In: Mono-
graphs on Pathology of laboratory animals. Urinary system. 
Second edition. Jones TC, Hard GC, Mohr U, eds. Springer, 
New York. 1998: 331–68.
51. Kunze E, Chowaniec J. Pathology of tumours in labo-
ratory animals. Tumours of the rat. Tumours of the urinary 
bladder. IARC Sci Publ 1990; 99: 345–97.
52. Kunze E, Gassner G. Modification of N-methyl-
N-nitrosourea-induced urinary bladder carcinogenesis in rats 
following stimulation of urothelial proliferation by a partial 
cystectomy. J Cancer Res Clin Oncol 1986; 112: 11–8. 
53. Kunze E, Graewe T, Scherber S, Weber J, Gellhar P. 
Cell cycle dependence of N-methyl-N-nitrosourea-induced 
tumour development in the proliferating, partially resected rat 
urinary bladder. Br J Exp Pathol 1989; 70: 125–42. 
54. Kunze E, Konnecke B, Nienaber C. Development of 
N-butyl-N-(hydroxybutyl)-nitrosamine-induced tumors in 
the partially resected, proliferating rat urinary bladder in de-
pendence upon the time of onset of stimulated DNA synthesis. 
Urol Res 1990; 18: 319–22. 
55. Kunze E, Schauer A, Schatt S. Stages of transformation 
in the development of N-butyl- transitional cell carcinomas in 
the urinary bladder of rats. Z Krebsforsch Klin Onkol 1976; 
87: 139–60. 
56. Lalich JJ. Experimentally induced uracil urolithiasis 
in rats. J Urol 1966; 95: 83–6. 
57. Magee PN, Barnes JM. Carcinogenic nitroso com-
pounds. Adv Cancer Res 1967; 10: 163–246. 
58. Mann AM, Masui T, Chlapowski FJ, Okamura T, 
Borgeson CD, Cohen SM. In vitro transformation of rat 
bladder epithelium by 2-amino-4-(5-nitro-2-furyl)thiazole. 
Carcinogenesis 1991; 12: 417–22. 
59. Masters JR, Petzoldt JL. In vitro studies on the 
pathogenesis of bladder cancer. Verh Dtsch Ges Pathol 1993; 
77: 157–60. 
60. Masui T, Dong Y, Yamamoto S, Takada N, Nakanishi H, 
Inada K, Fukushima S, Tatematsu M. p53 mutations in tran-
sitional cell carcinomas of the urinary bladder in rats treated 
with N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Lett 
1996; 105: 105–12. 
61. Masuko T, Sugahara K, Nakajima S, Hashimoto Y. 
Altered expression of immunohistochemically detected cy-
tochrome P-450 component(s) in nitrosamine-induced rat 
urinary bladder lesion. Jpn J Cancer Res 1987; 78: 840–5. 
62. Miller JA. Carcinogenesis by chemicals: an 
overview — G.H.A.Clowes memorial lecture. Cancer 
Res 1970; 30: 559–76. 
63. Murphy WM, Nagy GK, Rao MK, Soloway MS, 
Parija GC, Cox CE, 2nd Friedell GH. “Normal” urothelium 
in patients with bladder cancer: a preliminary report from the 
National Bladder Cancer Collaborative Group A. Cancer 
1979; 44: 1050–8.
64. Murphy WM, Irving CC. The cellular features of de-
veloping carcinoma in murine urinary bladder. Cancer 1981; 
47: 514–22. 
65. Murphy WM, Soloway MS. The effect of thio-TEPA 
on developing and established mammalian bladder tumors. 
Cancer 1980; 45: 870–5. 
66. Murphy WM, Soloway MS, Lin CJ. Morphologic 
effects of thio-TEPA on mammalian urothelium. Changes in 
abnormal cells. Acta Cytol 1978; 22: 550–4. 
67. Ogawa K, Kimoto N, Asamoto M, Nakanishi M, Taka-
hashi S, Shirai T. Aberrant expression of p27(Kip1) is associ-
ated with malignant transformation of the rat urinary bladder 
epithelium. Carcinogenesis 2000; 21: 117–21. 
68. Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, 
Fukushima S, Niijima T. Sequential changes of mouse bladder epi-
thelium during induction of invasive carcinomas by N-butyl-N-
(4-hydroxybutyl) nitrosamine. Cancer Res 1986; 46: 2001–4. 
69. Okajima E, Hiramatsu T, Hirao K, Ijuin M, Hirao Y, 
Babaya K, Ikuma S, Ohara S, Shiomi T, Hijioka T, Ohishi H. 
Urinary bladder tumors induced by N-butyl-N-(4-hydroxybu-
tyl) nitrosamine in dogs. Cancer Res 1981; 41: 1958–66. 
70. Oliveira PA, Palmeira C, Lourenço L, Lopes C. Evalua-
tion of DNA content in preneoplastic changes of mouse urinary 
bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. 
J Exp Clin Cancer Res 2005; 24: 207–14. 
71. Ota T, Asamoto M, Toriyama-Baba H, Yamamoto F, 
Matsuoka Y, Ochyia T, Sekiya T, Terada M, Akaza H, Tsuda H. 
Transgenic rats carrying copies of the human c-Ha-ras proto-
oncogene exhibit enhanced susceptibility to N-butyl-N-(4-
hydroxybutyl)nitrosamine bladder carcinogenesis. Carcino-
genesis 2000; 21: 1391–6. 
72. Oyasu R. Epithelial tumours of the lower urinary 
tract in humans and rodents. Food Chem Toxicol 1995; 
33: 747–55. 
73. Oyasu R, Iwasaki T, Matsumoto M, Hirao Y, Tabuchi Y. 
Induction of tumors in heterotopic bladder by topical applica-
tion of N-methyl-N-nitrosourea and N-butyl-N-(3-carboxy-
propyl) nitrosamine. Cancer Res 1978; 38: 3019–25. 
74. Ozaki K, Sukata T, Yamamoto S, Uwagawa S, Seki T, 
Kawasaki H, Yoshitake A, Wanibuchi H, Koide A, Mori Y, 
Fukushima S. High susceptibility of p53(+/-) knockout mice 
in N-butyl-N-(4-hydroxybutyl) nitrosamine urinary bladder 
carcinogenesis and lack of frequent mutation in residual allele. 
Cancer Res 1998; 58: 3806–11. 
75. Pamukcu AM, Erturk E, Yalciner S, Bryan GT. Histo-
genesis of urinary bladder cancer induced in rats by bracken 
fern. Invest Urol 1976; 14: 213–8. 
76. Perabo FG, Demant AW, Wirger A, Schmidt DH, Sitia M, 
Wardelmann E, Muller SC, Kohn EC. Carboxyamido-triazole 
(CAI) reverses the balance between proliferation and apoptosis in 
a rat bladder cancer model. Anticancer Res 2005; 25: 725–9. 
Experimental	Oncology	8,	–11,	006	(March)	 11
77. Raghavan D, Debruyne F, Herr H, Jocham D, Kakizoe T, 
Okajima E, Sandberg A, Tannock I. In: Developments in Blad-
der cancer. Experimental models of bladder cancer: A critical 
review. Alan R. New York: Liss, Inc., 1986: 171–208.
78. Ratliff  TL, Palmer JO, McGarr JA, Brown EJ. Intravesi-
cal Bacillus Calmette-Guerin therapy for murine bladder tumors: 
initiation of the response by fibronectin-mediated attachment of 
Bacillus Calmette-Guerin. Cancer Res 1987; 47: 1762–6. 
79. Russell PJ, Jingsley EA. In: Bladder cancer biology, 
diagnosis and management. Animal models for the study of 
bladder cancer. Syrigos NK, Skinner DG, eds. New York: 
Oxford University Press, 1999: 71–95.
80. Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, 
Jelbart M, Wass J, Zbroja RA, Vincent PC. Bladder cancer 
xenografts: a model of tumor cell heterogeneity. Cancer Res 
1986; 46: 2035–40. 
81. Sardon D, de la Fuente I, Calonge E, Perez-Alenza MD, 
Castano M, Dunner S, Pena L. H-ras immunohistochemical 
expression and molecular analysis of urinary bladder lesions 
in grazing adult cattle exposed to bracken fern. J Comp Pathol 
2005; 132: 195–201. 
82. Sens DA, Park S, Gurel V, Sens MA, Garrett SH, 
Somji S. Inorganic cadmium- and arsenite-induced malignant 
transformation of human bladder urothelial cells. Toxicol Sci 
2004; 79: 56–63. 
83. Shirai T. Etiology of bladder cancer. Semin Urol 1993; 
11: 113–26. 
84. Shirai T, Fukushima S, Hirose M, Ohshima M, Ito N. 
Epithelial lesions of the urinary bladder in three hundred and 
thirteen autopsy cases. Jpn J Cancer Res 1987; 78: 1073–80. 
85. Shirai T, Shibata M, Takahashi S, Tagawa Y, Imaida  K, 
Hirose M. Differences in cell proliferation and apoptosis between 
reversible and irreversible mucosal lesions associated with uracil-
induced urolithiasis in N-butyl-N-(4-hydroxybutyl)nitrosamine-
pretreated. Carcinogenesis 1995; 16: 501–5. 
86. Shirai T, Takahashi S. In: Monographs on pathology 
of laboratory animals. Papilloma, urinary bladder, rat. Urinary 
system. Second edition. Jones TC, Hard GC, Mohr U, eds. 
New York: Springer, 1998: 399–402.
87. Smith BL, Seawright AA, Ng JC, Hertle AT, Thom-
son JA, Bostock PD. Concentration of ptaquiloside, a major 
carcinogen in bracken fern (Pteridium spp.), from eastern 
Australia and from a cultivated worldwide collection held in 
Sydney, Australia. Nat Toxins 1994; 2: 347–53. 
88. Soloway MS. Intravesical and systemic chemotherapy 
of murine bladder cancer. Cancer Res 1977; 37: 2918–29. 
89. Spry LA, Zenser TV, Cohen SM, Davis BB. Role of 
renal metabolism and excretion in 5-nitrofuran-induced uro-
epithelial cancer in the rat. J Clin Invest 1985; 76: 1025–31.
90. Squire RA. In: Monographs on pathology of laboratory 
animals. Urinary system. Second edition. Classification and 
differential diagnosis of neoplasms, urinary tract, rat. Jones TC, 
Hard GC, Mohr U, eds.New York: Springer, 1998: 69–74.
91. Steinberg GD, Brendler CB, Squire RA, Isaacs JT. Experi-
mental intravesical therapy for superficial transitional cell carcinoma 
in a rat bladder tumor model. J Urol 1991; 145: 647–53. 
92. Stewart FA, Denekamp J, Hirst DG. Proliferation 
kinetics of the mouse bladder after irradiation. Cell Tissue 
Kinet 1980; 13: 75–89. 
93. Tamano S, Hagiwara A, Suzuki E, Okada M, Shi-
rai T, Fukushima S. Time- and dose-dependent induction 
of invasive urinary bladder cancers by N-ethyl-N-(4-
hydroxybutyl)nitrosamine in B6C3F1 mice. Jpn J Cancer Res 
1991; 82: 650–6. 
94. Tsuda H, Fukamachi K, Ohshima Y, Ueda S, Matsuo-
ka Y, Hamaguchi T, Ohnishi T, Takasuka N, Naito A. High 
susceptibility of human c-Ha-ras proto-oncogene transgenic 
rats to carcinogenesis: a cancer-prone animal model. Cancer 
Sci 2005; 96: 309–16. 
95. Tsuda H, Miyata Y, Hagiwara A, Hasegawa R, Shi-
rai T, Ito N. Damage and repair of DNA in urinary bladder 
epithelium of rats treated with N-butyl-N-(4-hydroxybutyl) 
nitrosamine. Gan 1977; 68: 781–3. 
96. Xiao Z, McCallum TJ, Brown KM, Miller GG, 
Halls SB, Parney I, Moore R. Characterization of a novel 
transplantable orthotopic rat bladder transitional cell tumour 
model. Br J Cancer 1999; 81: 638–46. 
97. Xiao Z, Brown K, Tulip J, Moore RB. Whole bladder 
photodynamic therapy for orthotopic superficial bladder can-
cer in rats: a study of intravenous and intravesical administra-
tion of photosensitizers. J Urol 2003; 169: 352–6.
98. Yamagiwa K and Ichikawa K. Experimental study of the 
pathogenesis of carcinoma. J Cancer Res 1918; iii: 1–29. 
99.Yamamoto S, Min W, Lee CC, Salim EI, Wanibuchi H, 
Sukata T, Fukushima S. Enhancement of urinary bladder carci-
nogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-
hydroxybutyl) nitrosamine. Cancer Lett 1999; 135: 137–44. 
Экспериментальные опухоли мочевого пузыря: 
модели на грызунах
Для изучения механизмов развития рака мочевого пузыря было создано несколько экспериментальных моделей на гры-
зунах. Целью обзора была сравнительная оценка различных экспериментальных моделей для изучения канцерогенеза 
мочевого пузыря, профилактики и терапии. За исключением трансгенных и нокаутных животных, для получения высокого 
выхода опухолей в любой экспериментальной модели требуется 8–12 мес. Модели спонтанного канцерогенеза мочевого 
пузыря крайне редки. Выбор экспериментальной модели с определенными параметрами определяет значимость получен-
ных результатов. В статье описаны различные методики, используемые для индукции рака мочевого пузыря in vivo,  ряд 
методических подходов, таких как культура клеток, имплантация опухоли и трансгенные модели рака мочевого пузыря 
и современные методы мониторинга опухолевой прогрессии. 
Ключевые слова: рак мочевого пузыря, экспериментальные модели, грызуны.
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